Bioenvision's Evoltra(R) Achieves High Response Rates In Adult AML

EDINBURGH, Scotland--(BUSINESS WIRE)--April 5, 2006--Bioenvision (Nasdaq: BIVN - News) today announced that an overall response had been achieved in 92% of patients over 60 yrs of age with acute myeloid leukemia (AML) given a combination of Evoltra® (clofarabine) and daunorubicin as first-line treatment. These interim data were presented at the British Society of Haematology 46th Annual Scientific Meeting in Edinburgh by Professor A. K. Burnett.